Welcome to our dedicated page for REPLIGEN SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REPLIGEN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REPLIGEN's regulatory disclosures and financial reporting.
Repligen Corporation reported Q3 2025 results with total revenue of $188.8 million and net income of $14.9 million, a turnaround from a $0.7 million loss a year ago. For the first nine months of 2025, revenue reached $540.3 million with net income of $35.6 million.
Cash and cash equivalents were $748.7 million, supporting a strong balance sheet with total assets of $2.92 billion. The company closed the 908 Devices bioprocessing analytics portfolio acquisition for $69.9 million in cash, recording provisional goodwill of $50.1 million and incurring $10.5 million in transaction and integration costs year to date. Contingent consideration fell to $7.6 million, producing gains of $4.1 million in Q3 and $12.1 million year to date.
The restructuring plan was completed in Q2 2025, with $4.1 million in related charges in the first nine months of 2025. The 1.00% Convertible Senior Notes due 2028 had a $537.9 million carrying amount and were not convertible for Q4 2025 under the indenture’s trading condition. Shares outstanding were 56,290,749 as of October 31, 2025.
Repligen Corporation filed an 8-K stating it announced financial results for the third quarter ended September 30, 2025. The company furnished the full text of the announcement as Exhibit 99.1, a press release dated October 28, 2025.
The information provided under Item 2.02 is furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference, except as expressly set forth by specific reference.
Repligen Corporation reporting person Olivier Loeillot, who is listed as both a Director and the Chief Executive Officer, recorded a sale of common stock on 10/02/2025. The filing shows 1,248 shares were disposed of at a price of $145.23 per share, with 42,939 shares remaining beneficially owned after the transaction. The reported sale represents shares withheld by the issuer to satisfy tax withholding obligations arising from the release of restricted stock units, not an open-market purchase or voluntary sale. The Form 4 was signed on 10/06/2025 by an attorney-in-fact on behalf of the reporting person.
Repligen Corp (RGEN) Chief Financial Officer Jason K. Garland reported a non-derivative disposition on 09/25/2025 involving 412 shares of Common Stock sold at a price of $121.68 per share. The filing shows 13,383 shares remained beneficially owned by the reporting person after the transaction. The form identifies the transaction as related to tax withholding: the 412 shares were withheld by the issuer to satisfy the reporting person's tax withholding obligations upon the release of restricted stock units.
Repligen Corp (RGEN) director Anthony Hunt exercised options and sold shares on 09/10/2025 under a documented plan. Mr. Hunt exercised a stock option to acquire 20,000 shares at an exercise price of $33.87, resulting in 20,000 newly acquired shares recorded in Table II. On the same date he sold multiple blocks of common stock under a 10(b)5-1 trading plan, with weighted-average sale prices reported at $116.34, $118.32, $119.64, $120.19, $121.42 and $122.23 for different tranches. After these transactions his direct beneficial ownership of common stock is reported as 100,743 shares and he beneficially owns 182,344 shares underlying options.
Repligen Corp (RGEN) filed a Form 144 reporting a proposed sale of 29,111 common shares through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $3,508,378.25 and approximately 56,257,618 shares outstanding. The filing shows 9,111 shares acquired via restricted stock vesting on 03/01/2022 as compensation, and 20,000 shares associated with options (options granted 03/01/2018) to be sold on 09/10/2025 for cash. The filer reports no sales in the past three months. The notice includes the filer’s attestation that they are not aware of any undisclosed material adverse information about the issuer.
T. Rowe Price Associates, Inc. filed an Amendment No. 6 to Schedule 13G reporting ownership of 3,429,547 shares of Repligen Corp common stock, representing 6.1% of the class. The filing shows T. Rowe Price has sole voting power over 3,170,704 shares and sole dispositive power over 3,429,435 shares. No shared voting or dispositive power is reported.
The filer certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing lists Maryland as the filer’s place of organization and provides issuer and filer addresses.
Repligen Corporation officer Violetta Hughes reported awards and option grants in a Form 4 filing. On 09/02/2025 she was awarded 4,142 restricted stock units, each representing a contingent right to one share; the RSUs vest in equal annual installments over five years beginning on the first anniversary of the grant and will be settled only in shares, so they are reported as 4,142 shares beneficially owned following the transaction. On the same date she acquired a stock option to buy 3,914 shares with an exercise price of $120.69 and an expiration date of 09/02/2035; those options also vest in equal annual instalments over five years. The Form 4 is signed by an attorney-in-fact and filed 09/04/2025.
Repligen Corp (RGEN) insider transaction summary. Olivier Loeillot, who serves as both Director and Chief Executive Officer, reported a transaction dated 09/03/2025 showing 2,506 shares of Repligen common stock were disposed of at a price of $116.18 per share. The filing explains these shares were withheld by the issuer to satisfy tax withholding obligations arising upon the release of restricted stock units. After the withholding, Loeillot beneficially owns 44,187 shares outright. The Form 4 was filed by one reporting person and signed on behalf of Loeillot by Jennifer Carmichael (Attorney in Fact) on 09/04/2025.
Violetta Hughes, identified as Chief Accounting Officer of Repligen Corporation (RGEN), filed an initial Form 3 reporting the event dated 09/01/2025. The filing states that no securities are beneficially owned by the reporting person. The form is signed by Violetta Hughes on 09/04/2025 and references an attached Power of Attorney (Exhibit 24.1). The document is an initial ownership disclosure and contains no entries in the non-derivative or derivative securities tables.